Keith Michael Sullivan, MD

Professor of Medicine
James B. Wyngaarden Professor of Medicine, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address sulli025@mc.duke.edu

Research areas

  • Late effects of cancer treatment and stem cell transplantation 
  • Chronic graft-versus-host disease 
  • Transplantation for sickle cell and autoimmune diseases 
  • Knowledge engineering

Overview
Early on, Dr. Sullivan and the team at Fred Hutchinson Cancer Research Center developed a systematic investigative approach for the diagnosis and treatment of chronic graft-versus-host disease (GVHD), the major cause of late morbidity and non-relapse mortality following allogeneic stem cell transplantation (SCT). As a result of this work, it became clear that blood and marrow transplant recipients require systematic long-term follow-up to evaluate and treat late complications of high-dose chemoradiotherapy and SCT.

The program grew into a large multidisciplinary team, resulting in improvement in patient outcome and quality of life. Through the late events project, he also contributed to outcomes research, computer decision support systems, and knowledge engineering for follow-up care. With quality of life as a focus, research pursued the application of SCT to diseases with high morbidity but little immediate mortality. For young patients with advanced, symptomatic sickle cell disease, myeloablative conditioning and SCT from an HLA-identical sibling has led to an 86% long-term survival free of sickle cell disease. For individuals with autoimmune diseases such as multiple sclerosis, scleroderma, and systemic lupus erythematosus, current therapy is often incomplete and significant morbidity from the disease or its treatment is observed.

Recent preclinical and clinical data suggest that high-dose immunosupression and SCT can halt the progression and, in some settings, reverse the course of autoimmune diseases. Since his arrival at Duke University, over 30 centers nationwide are participating in Duke-led phase II and III trials to test the toxicity, efficacy, and quality of life following autologous and allogeneic stem cell transplantation for autoimmune diseases.

These trials will also serve as platforms to study the immune repertoire and mechanistic pathways before and after SCT to gain greater insight into the basic mechanisms of autoimmunity.

A national repository of tissue and cell specimens is also part of these NIH-supported trials to further promote scientific study from these unique patients.

In Their Words

Education and Training

  • M.D., Indiana University at Indianapolis, 1971

Publications

Syrjala, K. L., M. K. Chapko, P. P. Vitaliano, C. Cummings, and K. M. Sullivan. “Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning..” Bone Marrow Transplant 11, no. 4 (April 1993): 319–27.

PMID
8485479
Scholars@Duke

Oliveira, J. S. de, S. B. Auerbach, K. M. Sullivan, and G. E. Sale. “Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan..” Bone Marrow Transplant 11, no. 2 (February 1993): 163–67.

PMID
8435665
Scholars@Duke

Beatty, P. G., C. Anasetti, J. A. Hansen, G. M. Longton, J. E. Sanders, P. J. Martin, E. M. Mickelson, S. Y. Choo, E. W. Petersdorf, and M. S. Pepe. “Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus..” Blood 81, no. 1 (January 1, 1993): 249–53.

PMID
8417795
Scholars@Duke

Clift, R. A., C. D. Buckner, F. R. Appelbaum, G. Schoch, F. B. Petersen, W. I. Bensinger, J. Sanders, K. M. Sullivan, R. Storb, and J. Singer. “Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia..” J Clin Oncol 10, no. 11 (November 1992): 1723–29. https://doi.org/10.1200/JCO.1992.10.11.1723.

PMID
1403055
Full Text

Tanaka, K., T. Aki, H. M. Shulman, K. M. Sullivan, A. Tanaka, and R. Nagasako. “Two cases of transfusion-associated graft-vs-host disease after open heart surgery..” Arch Dermatol 128, no. 11 (November 1992): 1503–6.

PMID
1444505
Scholars@Duke

Anasetti, C., P. J. Martin, R. Storb, F. R. Appelbaum, P. G. Beatty, J. Davis, K. Doney, H. F. Hill, P. Stewart, and K. M. Sullivan. “Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody..” Transplantation 54, no. 5 (November 1992): 844–51. https://doi.org/10.1097/00007890-199211000-00015.

PMID
1440852
Full Text

Nash, R. A., M. S. Pepe, R. Storb, G. Longton, M. Pettinger, C. Anasetti, F. R. Appelbaum, R. A. Bowden, H. J. Deeg, and K. Doney. “Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate..” Blood 80, no. 7 (October 1, 1992): 1838–45.

PMID
1391947
Scholars@Duke

Storb, R., M. Pepe, H. J. Deeg, C. Anasetti, F. R. Appelbaum, W. Bensinger, C. D. Buckner, R. A. Cliff, K. Doney, and J. Hansen. “Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia..” Blood 80, no. 2 (July 15, 1992): 560–61.

PMID
1627810
Scholars@Duke

Petersen, F. B., C. D. Buckner, F. R. Appelbaum, J. E. Sanders, W. I. Bensinger, R. Storb, H. J. Deeg, R. P. Witherspoon, K. M. Sullivan, and R. A. Clift. “Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study..” Bone Marrow Transplant 10, no. 1 (July 1992): 83–88.

PMID
1515884
Scholars@Duke

Storb, R., P. Martin, H. J. Deeg, J. E. Sanders, M. Pepe, J. Singer, C. Anasetti, P. Stewart, F. R. Appelbaum, and K. M. Sullivan. “Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia..” Blood 79, no. 11 (June 1, 1992): 3091–92.

PMID
1586751
Scholars@Duke

Pages